Brought to you by 
Denali Therapeutics brings in $130mm through Series B round
15 Sep 2017
Executive Summary
Denali Therapeutics Inc. (neurodegenerative disease drug development) raised $130mm through its Series B round. The UK-based mutual fund Baillie Gifford led, and was joined by all of Denali's founding investors including Fidelity Biosciences (now F-Prime), Arch Venture Partners, Flagship Ventures, Alaska Permanent Fund (represented by Crestline Investors), and additional new and large institutional investors. Proceeds will fund pipeline activities including work on the company's blood-brain barrier delivery technology. Denali has now raised almost $350mm since its formation in 2015.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Denali Therapeutics brings in $130mm through Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice